Rapid Micro Biosystems, Inc.
NASDAQ:RPIDMedical - Devices
+$0.03 today
- Market cap
- $50.31M
- Beta
- 1.46
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$1.10
Volume 0.17M
Average 0.18M
RPID Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Rapid Micro Biosystems, Inc.NASDAQ: RPID
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $3.36M fell 7.3% year over year, in line with the -7.2% change in trailing-twelve-month research & development. Sequentially, it rose 4.3% from the prior quarter. Over 3 fiscal years it compounded at +1.9% a year.
Context
- Research & development amounted to 40.5% of revenue in FY2025, down 11.5 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -7.3% toward the trailing-twelve-month pace of -7.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 13.6M USD
- Year-over-year change
- -6.8%
- 4-year CAGR
- +8.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.6M | -6.8% |
| FY2024 | 2024-12-31 | 14.6M | +13.9% |
| FY2023 | 2023-12-31 | 12.82M | -0.4% |
| FY2022 | 2022-12-31 | 12.87M | +31.5% |
| FY2021 | 2021-12-31 | 9.78M | — |
Research & Development vs competitors
How RPID compares with its peers on the latest reported figures
- RPID's LTM Mar 2026 research & development of $13.34M is the 5th highest of the 9 companies compared; the peer median is $14M.
- Its year-over-year change of -7.2% is the 5th highest of 9, against a peer median of -6.9%.
- Research & development amounts to 38.8% of revenue for RPID, versus a peer median of 21.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.45M | -22.6% | +7.0% | — | |
| LTM Mar 2026 | $20.18M | -5.9% | +14.6% | 27.9% | |
| LTM Mar 2026 | $18.17M | +11.9% | +8.6% | — | |
| LTM Mar 2026 | $15.13M | +46.7% | -20.4% | 14.1% | |
| LTM Mar 2026 | $13.34M | -7.2% | +1.9% | 38.8% | |
| LTM Mar 2026 | $12.87M | -10.5% | -2.6% | 22573.7% | |
| LTM Mar 2026 | $5.47M | +1.0% | -21.9% | 9.5% | |
| LTM Mar 2026 | $5.46M | -7.8% | +691.2% | 106.3% | |
| LTM Mar 2026 | $3.33M | -25.7% | -9.5% | 6.0% | |
| Peer median (excluding RPID) | $14M | -6.9% | +2.2% | 21.0% | |
Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 23.23M | 17.13M | 22.52M | 28.05M | 33.59M |
| Cost of Revenue | 30.97M | 25.67M | 28M | 28.16M | 25.98M |
| Gross Profit | (7.74M) | (8.54M) | (5.49M) | (109K) | 7.61M |
| Gross Margin | -33.3% | -49.8% | -24.4% | -0.4% | 22.7% |
| Research & Development | 9.78M | 12.87M | 12.82M | 14.6M | 13.6M |
| Selling, General & Admin | 29.71M | 41.81M | 38.26M | 35.21M | 34.84M |
| Operating Expenses | 39.49M | 54.68M | 51.08M | 49.81M | 55M |
| Depreciation & Amortization | 1.53M | 2.84M | 3.11M | 3.36M | 3.25M |
| EBITDA | (69.25M) | (58.55M) | (49.33M) | (43.51M) | (42.74M) |
| EBITDA Margin | -298.1% | -341.7% | -219.1% | -155.1% | -127.3% |
| Operating Income | (47.23M) | (63.22M) | (56.56M) | (49.92M) | (47.39M) |
| Operating Margin | -203.3% | -369.0% | -251.2% | -178.0% | -141.1% |
| Interest Income | 0 | 1.78M | 4.21M | 3.16M | 1.51M |
| Interest Expense | 2.65M | 0 | 0 | 0 | 1.09M |
| Other Income / Expenses | (26.2M) | 1.84M | 4.13M | 3.05M | 309K |
| Income Before Tax | (73.43M) | (61.38M) | (52.44M) | (46.87M) | (47.08M) |
| Pre-Tax Margin | -316.1% | -358.3% | -232.9% | -167.1% | -140.2% |
| Income Tax Expense | 91K | (576K) | 31K | 22K | 40K |
| Net Income | (73.52M) | (60.81M) | (52.47M) | (46.89M) | (47.12M) |
| Net Margin | -316.5% | -354.9% | -233.0% | -167.2% | -140.3% |
| EPS (Basic) | (1.88) | (1.43) | (1.22) | (1.08) | (1.05) |
| EPS (Diluted) | (1.88) | (1.43) | (1.22) | (1.08) | (1.05) |
| Weighted Avg Shares | 41.47M | 42.45M | 43.02M | 43.58M | 44.68M |
| Weighted Avg Shares (Diluted) | 41.47M | 42.45M | 43.02M | 43.58M | 44.68M |
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.